Metropolis Healthcare Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St

August 06, 2024

Metropolis Healthcare (NSE:METROPOLIS) Full Year 2024 Results

Key Financial Results

Revenue: ₹12.1b (up 5.2% from FY 2023).
Net income: ₹1.28b (down 11% from FY 2023).
Profit margin: 11% (down from 12% in FY 2023). The decrease in margin was driven by higher expenses.
EPS: ₹24.95 (down from ₹27.91 in FY 2023).

revenue-and-expenses-breakdown — NSEI:METROPOLIS Revenue and Expenses Breakdown August 6th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Metropolis Healthcare Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates by 5.7%.

The primary driver behind last 12 months revenue was the India segment contributing a total revenue of ₹11.1b (92% of total revenue). The largest operating expense was General & Administrative costs, amounting to ₹3.81b (47% of total expenses). Explore how METROPOLIS's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Healthcare industry in India.

Performance of the Indian Healthcare industry.

The company's shares are down 1.2% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on Metropolis Healthcare's balance sheet.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com